We are looking for early-stage longevity start-ups and potential IP spin-outs. Please send us your pitch deck if your company has never been funded before and refers to the following categories:
Tissue, and Organ Reconstruction
Scalable regeneration technologies, including in situ tissue renewal, organoids, and organ replacement strategies.
Advanced Delivery and Clearance Technologies
Organ-targeted delivery, BBB-crossing systems, organelle-level targeting, and platforms removing accumulated biological waste.
Immune Rejuvenation and Epigenetic Therapies
Scalable interventions that can be applied across multiple age-related conditions.
Mitochondrial Repair & Maintenance
Translatable approaches to mitophagy, mitochondrial biogenesis, and mtDNA stability with multi-indication potential.
Enabling Technologies
Platforms useful across the entire longevity ecosystem: organ-on-chip systems, microphysiological testbeds, advanced drug-screening platforms, precision delivery systems, and supportive biomanufacturing tools.
Cryopreservation & Biostasis
Technologies with broad applicability to cells, tissues, and organs.
Brain Replacement
Artificial Blood
Longevity Therapies for Animals
Veterinary rejuvenation technologies that mirror human-directed longevity approaches and are scalable across multiple indications.
Targeted Cellular Senescence Modulation
Only precise, biomarker-validated approaches with clear therapeutic translation.
Genomic Stability & Proteostasis
Translational tools addressing multiple disorders, backed by safety and off-target data.
Non-scalable Single-Indication Drugs
Solutions targeting only one narrowly defined disease or application.
Xenotransplantation and AI-enabled Discovery
Considered only when accompanied by intermediate commercializable tools or full wet-lab validation.
Metabolic Modulation
Novel, differentiated mechanisms beyond traditional nutraceutical pathways.
Supplements, wellness products, non-actionable diagnostics, general AI discovery without proprietary data or wet lab validation, and non-specific systemic senolytics.